Comment on: Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30625 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Saba Mushtaq und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Department, Ayub Medical College, Abbottabad, Pakistan. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Pain Measurement. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
To the Editor: We read Angela Pascale et al.’s “Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes” with excitement.1 Thisworkmayenhance therapy, prognoses, ormechanistic knowledge, which is crucial for intervention and prevention. It would be a privilege to add a few additional points. Hydroxyurea (hydroxycarbamide) is used to treat sickle cell disease (SCD) as reported in a 2022 systematic review2 and a 2018 study.3 The research has indicated an important therapy option that may improve pain outcomes in children with SCD. Studies on pain variability in the context of hydroxyurea treatment could have augmented the authors’ findings. The authors might have explained how pain variability measurements align with existing pain treatment strategies. Research from 2019 addresses pediatric and adolescent SCD pain treatment and theirwork illuminates therapeutic practice techniques.4 A 2022 cluster-analytic analysis identified pediatric SCD chronic pain subtypes. This research divides patients into subgroups to look at pain variability differently.5 The authors might have examined intraindividual pain variability and subgroup membership by including these subgroup classifications. In 2019, thePediatric Pain ScreeningToolwas used to assess chronic pain risk factors in sickle cell patients. The tool helped identify children with persistent SCD pain or at risk of poor outcomes.6 Other researchonpediatric sickle cell pain, sleep, andemotionmay contribute to our understanding of pain variability in children with SCD. A study from 2021 examined the link between the daily sleep quality-pain severity in adolescents with SCD. Poor sleep and severe pain cycled every day due to low positive affect. High negative affect enhanced the connection between high pain intensity and poor sleep quality that night.7 Research from 2022 investigated sleep disruptions and neurocognitive performance in pediatric SCD.8 This study’s results could broaden expanded the discussion given the interrelatedness of pain, sleep, and neurocognitive performance. Gil et al.9 examined SCD children and adolescents pain frequency and coping techniques throughout time. This previous research sheds light on this population’s long-term discomfort. A comparison of the authors’ findings with those of Gil et al.’s could have deepened our understanding of pain variability and its lifelong trajectory. The study fills a critical gap in the literature. However, more pertinent studies may have enriched the debate. A 2020 primary care update on SCD emphasizes comprehensive treatment strategies10 and research from the same year research outlines standard SCD complication therapy, including pain management.11 Finally, a 2022 secondary analysis of the Pain in Sickle Cell Epidemiology Study examined intraindividual pain variability and pain phenotypes.12 The research only recruited children with SCD from only three regional pediatric clinics in the United States, which may restrict its generalizability. The research also used youth-reported pain data, whichmay be subject to bias. In conclusion, we thank the authors for their valuable study on this topic. We believe this study will inspire future research and improve SCD care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Medicine Department, Ayub Medical College, Abbottabad, Pakistan.
- Shaheed Mohtarma Benazir Bhutto Medical College Lyari Karachi, Karachi, Pakistan.
- Dow University of Health Sciences, Karachi, Pakistan.
ORCID-Profile: Saba Mushtaq, Satesh Kumar
Zitieren
APA
Mushtaq, S., Kumar, S., & Khatri, M. (2023). Comment on: Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30625
Vancouver
Mushtaq S, Kumar S, Khatri M. Comment on: Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30625
BibTeX
@article{Mushtaq2023,
author = {Mushtaq, Saba and Kumar, Satesh and Khatri, Mahima},
title = {Comment on: Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30625}
}
EUVIMED